TY - JOUR
T1 - Supportive care for the patient with Alzheimer's disease.
AU - Jann, M. W.
AU - Brandt, N.
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2000
Y1 - 2000
N2 - The prevalence of AD, the most common form of dementia, is likely to double in the next 20 years. Although the cause of AD is unknown, risk factors include aging, genetic predisposition, and head trauma. The cholinesterase inhibitors (tacrine, donepezil, and rivastigmine) are the only FDA-approved class of medications for AD. Behavioral problems associated with AD are a major reason for admission to long-term care facilities and a common cause of caregiver "burnout" or stress.
AB - The prevalence of AD, the most common form of dementia, is likely to double in the next 20 years. Although the cause of AD is unknown, risk factors include aging, genetic predisposition, and head trauma. The cholinesterase inhibitors (tacrine, donepezil, and rivastigmine) are the only FDA-approved class of medications for AD. Behavioral problems associated with AD are a major reason for admission to long-term care facilities and a common cause of caregiver "burnout" or stress.
UR - http://www.scopus.com/inward/record.url?scp=0034266164&partnerID=8YFLogxK
U2 - 10.1016/s1086-5802(16)31193-7
DO - 10.1016/s1086-5802(16)31193-7
M3 - Article
C2 - 11029868
AN - SCOPUS:0034266164
SN - 1086-5802
VL - 40
SP - S50-51
JO - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
JF - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
IS - 5 Suppl 1
ER -